EnteroBiotix Limited operates as a clinical-stage biopharmaceuticals company focused on the development of innovative microbial therapies for unmet medical needs. Founded in 2017, the company’s registered with SC559230 and maintains an active status under SIC Code – 72110 – Research and experimental development on biotechnology. The company is headquartered at Phoenix House, Phoenix Crescent, Bellshill, ML4 3NJ within Scotland. EnteroBiotix specializes in the full-spectrum microbial therapies market, aiming to address a range of therapeutic areas with potential for significant clinical impact. Their core technology platform leverages advanced genetic engineering and metabolic pathway modulation to create novel microbial entities designed to treat complex diseases. The company’s strategic focus centers on developing treatments that target specific biological pathways influencing disease progression. EnteroBiotix is currently operating as a Skilled Worker visa holder with an A rating, indicating a strong commitment to performance within their role. The company's international presence includes collaborations and partnerships across multiple global regions, demonstrating its ambition for expanding market access. Their business model involves significant investment in research and development activities centered on microbial therapeutics.

EnteroBiotix Limited operates as a clinical-stage biopharmaceuticals company focused on the development of innovative microbial therapies for unmet medical needs. Founded in 2017, the company’s registered with SC559230 and maintains an active status under SIC Code – 72110 – Research and experimental development on biotechnology. The company is headquartered at Phoenix House, Phoenix Crescent, Bellshill, ML4 3NJ within Scotland. EnteroBiotix specializes in the full-spectrum microbial therapies market, aiming to address a range of therapeutic areas with potential for significant clinical impact. Their core technology platform leverages advanced genetic engineering and metabolic pathway modulation to create novel microbial entities designed to treat complex diseases. The company’s strategic focus centers on developing treatments that target specific biological pathways influencing disease progression. EnteroBiotix is currently operating as a Skilled Worker visa holder with an A rating, indicating a strong commitment to performance within their role. The company's international presence includes collaborations and partnerships across multiple global regions, demonstrating its ambition for expanding market access. Their business model involves significant investment in research and development activities centered on microbial therapeutics.